Neurocrine Biosciences, Inc. (NBIX)
164.63
+4.87
(+3.05%)
USD |
NASDAQ |
Nov 06, 16:00
164.65
+0.02
(+0.01%)
After-Hours: 20:00
Neurocrine Biosciences Research and Development Expense (Annual) : 1.016B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 1.016B |
| December 31, 2024 | 707.60M |
| December 31, 2023 | 547.20M |
| December 31, 2022 | 448.70M |
| December 31, 2021 | 317.20M |
| December 31, 2020 | 266.40M |
| December 31, 2019 | 192.59M |
| December 31, 2018 | 160.52M |
| December 31, 2017 | 121.83M |
| December 31, 2016 | 94.29M |
| December 31, 2015 | 81.49M |
| December 31, 2014 | 46.42M |
| December 31, 2013 | 39.25M |
| Date | Value |
|---|---|
| December 31, 2012 | 37.16M |
| December 31, 2011 | 30.95M |
| December 31, 2010 | 31.15M |
| December 31, 2009 | 33.71M |
| December 31, 2008 | 55.29M |
| December 31, 2007 | 77.08M |
| December 31, 2006 | 94.88M |
| December 31, 2005 | 106.63M |
| December 31, 2004 | 115.07M |
| December 31, 2003 | 177.27M |
| December 31, 2002 | 108.94M |
| December 31, 2001 | 74.27M |
| December 31, 2000 | 40.23M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Amgen, Inc. | 6.974B |
| Halozyme Therapeutics, Inc. | 81.49M |
| BioCryst Pharmaceuticals, Inc. | 164.74M |
| Iovance Biotherapeutics, Inc. | 300.27M |
| Precigen, Inc. | 40.06M |